MARATTO

article · The Egyptian Journal of Neurology Psychiatry and Neurosurgery

Early peripheral blood gene expression (Cyp4A11 and Cyp2E1) in cases of brain ischemia in addict cases admitted to Benha university hospital

20241 citationOpen accessBenha University

Abstract

Abstract Background Stroke is a major neurological disorder often exacerbated by substance abuse, including tramadol and cannabis. Understanding the molecular mechanisms underlying stroke pathogenesis in drug users can improve diagnosis and treatment. This study explores the roles of CYP4A11, CYP2E1, miR-27b, and miR-214-3p in the pathogenesis of stroke and their potential as diagnostic markers in individuals using tramadol and cannabis. Results Our findings indicate that CYP4A11 and CYP2E1 are significantly upregulated in the brain tissues of stroke patients who use tramadol and cannabis. Additionally, miR-27b and miR-214-3p levels were markedly altered, suggesting their involvement in stroke pathogenesis. The combined analysis of these biomarkers provided a robust diagnostic model with high sensitivity and specificity for identifying stroke in the context of drug addiction. Conclusions CYP4A11, CYP2E1, miR-27b, and miR-214-3p play critical roles in the pathogenesis of stroke in tramadol and cannabis users. These biomarkers hold promise as diagnostic tools, offering potential for early detection and personalized treatment strategies for stroke in drug-addicted populations. Further research is warranted to validate these findings and explore their therapeutic implications.

Research topics

  • Cannabis and Cannabinoid Research
  • Forensic Toxicology and Drug Analysis
  • Alcohol Consumption and Health Effects

Sustainable Development Goals

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.1186/s41983-024-00926-5

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.